Vyant Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vyant Bio, Inc. - overview
Established
1999
Location
Cherry Hill, NJ, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded in 1999, Vyant Bio, Inc. formerly known as Cancer Genetics, Inc. operates as a biotechnology company that focuses on discovering drugs for complex neurodevelopmental and neurodegenerative disorders. The company is traded on the Nasdaq under the symbol VYNT.
As of November 2022, the company has offices in Europe and Australia and is led by its CEO Mr. John Roberts. Vyant Bio, Inc. develops AnalytiX, a central nervous system (CNS) drug discovery platform that combines human-derived organoid models of brain disease, scaled biology, and machine learning.
The company also focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD), and familial Parkinson's disease (PD). The company has generated total revenue of USD 0. 98 million in the fiscal year 2021.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Medical Software
Website
www.vyantbio.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Vyant Bio, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | VivoPharm, LLC | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.